



FOR IMMEDIATE RELEASE

Tokyo, April 22, 2020

Listing on the Japanese National Health Insurance Drug Price List and Launch of CORECTIM[®] Ointment 0.5% for the Treatment of Atopic Dermatitis in Japan

Japan Tobacco Inc. (JT) (TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) announced today that drug price of CORECTIM[®] Ointment 0.5% (generic name: delgocitinib), a Janus kinase (JAK) inhibitor, was placed on the Japanese National Health Insurance (NHI) drug price list as of today. On January 23, 2020, JT received manufacturing and marketing approval for this drug for an indication of atopic dermatitis in Japan. Torii plans to launch the drug in Japan on June 24, 2020.

CORECTIM[®] Ointment 0.5% is a non-steroidal topical product and the world's first topical JAK inhibitor that improves atopic dermatitis by inhibiting the action of JAKs, which play a key role in immune activation signaling in cells, by suppressing the overactivation of immune responses. In the Phase 3 comparative clinical study in patients with atopic dermatitis (aged ≥ 16) for CORECTIM[®] Ointment 0.5% conducted in Japan, the primary endpoint of efficacy, the percentage change of the mEASI score* from baseline, has met superiority to the placebo, and safety of long-term administration was also confirmed.

JT and Torii expect CORECTIM[®] Ointment 0.5% to be a new option of treatment for patients with atopic dermatitis in Japan.

In addition, the Phase 3 clinical study in pediatric patients with atopic dermatitis (aged 2 to <16) for delgocitinib is being conducted in Japan.

* mEASI score (modified) is the Eczema Area and Severity Index (EASI) score excluding the score for the head and neck from. The EASI is a tool used to measure the extent area and severity of atopic dermatitis.

CORECTIM® Ointment 0.5%

Product Name:	CORECTIM® Ointment 0.5%
Generic Name:	Delgocitinib
Indications:	Atopic Dermatitis
Package:	5 g (10 tubes)
Dosage and Administration:	For adults, apply an appropriate amount of ointment to the affected areas twice daily. The dose applied should not exceed 5 g per dosing.
NHI Drug Price:	¥ 139.70 (0.5% 1 g)
Approval Date:	January 23, 2020
NHI Pricing Date:	April 22, 2020
Launch Date:	June 28, 2020
Manufacturing and Distributor:	Japan Tobacco Inc.
Distributor:	Torii Pharmaceutical Co., Ltd.

ABOUT Atopic Dermatitis

Atopic dermatitis is a chronic and pruritic inflammatory skin disease. It is thought to develop through exposure to various irritants or allergens for patients with a physiological abnormality of the skin (dry skin and abnormal skin barrier function).

###

Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With approximately 62,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its tobacco vapor products under its Ploom brand and various e-cigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit <https://www.jt.com/>.

Contact for Japan Tobacco Inc.:

Dinesh Babu Thotakura, General Manager
Media and Investor Relations Division
Japan Tobacco Inc. Tokyo: +81-3-5572-4292

E-mail: jt.media.relations@jt.com

Contact for Torii Pharmaceutical Co., Ltd.:

Corporate Planning Department
(Public Relations)
Torii Pharmaceutical Co., Ltd.
Tokyo: +81-3-3231-6814

E-mail: webmaster@torii.co.jp